Y-mAbs Therapeutics (NASDAQ:YMAB) Given “Buy” Rating at HC Wainwright

Share on StockTwits

Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued to clients and investors on Monday, The Fly reports. They currently have a $40.00 target price on the stock, up from their previous target price of $36.00. HC Wainwright’s target price would indicate a potential upside of 77.30% from the company’s current price.

The analysts wrote, “We have assessed Y-mAbs using a discounted cash flow (DCF)-based methodology, which yields a total enterprise value of $1.45B for the company based solely on the future sales of naxitamab and omburtamab.””

Separately, Zacks Investment Research raised Y-mAbs Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, March 15th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Y-mAbs Therapeutics has a consensus rating of “Buy” and an average price target of $30.80.

Shares of NASDAQ YMAB opened at $22.56 on Monday. The company has a current ratio of 13.30, a quick ratio of 13.30 and a debt-to-equity ratio of 0.02. Y-mAbs Therapeutics has a 1-year low of $15.17 and a 1-year high of $31.00. The stock has a market cap of $738.58 million and a price-to-earnings ratio of -15.04.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Friday, March 22nd. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.11). On average, research analysts expect that Y-mAbs Therapeutics will post -1.95 earnings per share for the current fiscal year.

In other news, insider Thomas Gad sold 6,000 shares of the company’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $20.61, for a total transaction of $123,660.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders have sold 270,000 shares of company stock valued at $6,888,700.

Large investors have recently added to or reduced their stakes in the company. Citigroup Inc. bought a new position in Y-mAbs Therapeutics in the 4th quarter worth approximately $37,000. Strs Ohio purchased a new stake in Y-mAbs Therapeutics during the 4th quarter valued at $38,000. BNP Paribas Arbitrage SA purchased a new stake in Y-mAbs Therapeutics during the 1st quarter valued at $38,000. New York State Common Retirement Fund purchased a new stake in Y-mAbs Therapeutics during the 1st quarter valued at $63,000. Finally, American International Group Inc. purchased a new stake in Y-mAbs Therapeutics during the 4th quarter valued at $93,000. 24.80% of the stock is owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Featured Article: What is a Real Estate Investment Trust (REIT)?

The Fly

Analyst Recommendations for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.